New anti-cancer strategies: epigenetic therapies and biomarkers - PubMed (original) (raw)

Review

. 2005 May 1:10:1897-931.

doi: 10.2741/1668.

Affiliations

• PMID: 15769674
• DOI: 10.2741/1668

Review

New anti-cancer strategies: epigenetic therapies and biomarkers

Curtis Balch et al. Front Biosci. 2005.

Abstract

Epigenetics is the study of chromatin modifications that affect gene expression without altering DNA nucleotide sequences. This review highlights a prominent role for epigenetic therapies, particularly those that reverse aberrant DNA methylation and histone acetylation, in the potential treatment of cancer. Administration of such therapies to reverse epigenetic "silencing" of tumor suppressors, including genes involved in chemotherapy responses, could prove useful in the management of cancer patients. In this review, we summarize recent advances in the use of methyltransferase and histone deacetylase inhibitors and possible synergistic combinations of these to achieve maximal tumor suppressor gene re-expression. Moreover, when used in combination with conventional chemotherapeutic agents, epigenetic-based therapies may provide a means to resensitize drug-resistant tumors to established treatments. As specific, aberrant epigenetic modifications are frequently associated with distinct cancer types, and likely occur early in tumorigenesis, these have potential utility as biomarkers. Finally, future directions are addressed, including alternative epigenetic targets, gene-specific modifications, and the use of bioinformatics.

PubMed Disclaimer

Similar articles

• The epigenetics of ovarian cancer drug resistance and resensitization.
  Balch C, Huang TH, Brown R, Nephew KP. Balch C, et al. Am J Obstet Gynecol. 2004 Nov;191(5):1552-72. doi: 10.1016/j.ajog.2004.05.025. Am J Obstet Gynecol. 2004. PMID: 15547525 Review.
• Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.
  Ganesan A, Nolan L, Crabb SJ, Packham G. Ganesan A, et al. Curr Cancer Drug Targets. 2009 Dec;9(8):963-81. doi: 10.2174/156800909790192428. Curr Cancer Drug Targets. 2009. PMID: 20025605 Review.
• Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
  Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M. Sigalotti L, et al. J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066. J Cell Physiol. 2007. PMID: 17458893 Review.
• [Development of novel epigenetic molecular-targeting agents].
  Sowa Y, Sakai T. Sowa Y, et al. Nihon Rinsho. 2015 Aug;73(8):1263-7. Nihon Rinsho. 2015. PMID: 26281676 Review. Japanese.
• Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
  Zahnow CA, Topper M, Stone M, Murray-Stewart T, Li H, Baylin SB, Casero RA Jr. Zahnow CA, et al. Adv Cancer Res. 2016;130:55-111. doi: 10.1016/bs.acr.2016.01.007. Epub 2016 Mar 2. Adv Cancer Res. 2016. PMID: 27037751 Review.

Cited by

• Minireview: epigenetic changes in ovarian cancer.
  Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Balch C, et al. Endocrinology. 2009 Sep;150(9):4003-11. doi: 10.1210/en.2009-0404. Epub 2009 Jul 2. Endocrinology. 2009. PMID: 19574400 Free PMC article. Review.
• The pursuit of oncotargets through understanding defective cell regulation.
  Qiao M, Shi Q, Pardee AB. Qiao M, et al. Oncotarget. 2010 Nov;1(7):544-551. doi: 10.18632/oncotarget.189. Oncotarget. 2010. PMID: 21317450 Free PMC article. Review.
• DFNA5 promoter methylation a marker for breast tumorigenesis.
  Croes L, de Beeck KO, Pauwels P, Vanden Berghe W, Peeters M, Fransen E, Van Camp G. Croes L, et al. Oncotarget. 2017 May 9;8(19):31948-31958. doi: 10.18632/oncotarget.16654. Oncotarget. 2017. PMID: 28404884 Free PMC article.
• Epigenetics and human disease: translating basic biology into clinical applications.
  Rodenhiser D, Mann M. Rodenhiser D, et al. CMAJ. 2006 Jan 31;174(3):341-8. doi: 10.1503/cmaj.050774. CMAJ. 2006. PMID: 16446478 Free PMC article. Review.
• Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.
  Mirza S, Sharma G, Pandya P, Ralhan R. Mirza S, et al. Mol Cell Biochem. 2010 Sep;342(1-2):101-9. doi: 10.1007/s11010-010-0473-y. Epub 2010 May 9. Mol Cell Biochem. 2010. PMID: 20455010

Publication types

MeSH terms

Substances

LinkOut - more resources

• Research Materials

  • NCI CPTC Antibody Characterization Program